For years, dashboards have been the standard way Medical Affairs teams monitor expert activity, scientific conversations, and engagement performance. They organize information into clear visuals and reports, helping teams track what is happening across therapeutic areas and expert networks.
Static expert lists can’t capture shifting influence in today’s fast-moving healthcare environment. With a dynamic KOL database and advanced KOL analysis tools, teams gain real-time insights into expert behavior, sentiment, and emerging KEEs for smarter engagement.
Speaker selection has traditionally followed a familiar pattern: identify well-known experts, validate credentials, and build programs around visibility and reputation. While this approach checks many boxes, it often misses the most important question:
Neolytica blends KOL sentiment analysis, behavioral insights, and network mapping to reveal influential local clinicians, improving pharma engagement and strategy.
Medical and commercial teams rarely disagree on objectives. Both want relevant conversations, credible science, and measurable impact. Yet in practice, alignment often breaks down, not because of intent, but because teams are working with partial views of influence.
Field and medical teams spend countless hours planning who to meet, what to discuss, and how to advance scientific conversations. But despite all this effort, one question keeps coming back:
In medical affairs and field engagement, timing and context often decide the quality of every conversation. You can have the best data, the strongest story, and the right expert, but if the dialogue doesn’t align with what matters to them today, the opportunity fades.
Scientific engagement works best when it’s synchronized with how HCPs are thinking and talking today, not last quarter. That’s why digital sentiment, the tone and direction of expert conversations across professional forums, congress backchannels, preprints, and selected social channels, belongs at the center of modern scientific engagement planning.
KEE targeting has evolved. Version 1.0 was spreadsheets of “top names.” Version 2.0 chased digital activity, who posts, where, and how often. KEE Targeting 3.0 goes further: it connects role, behavior, and impact to reveal who actually moves clinical decisions and why. If your medical affairs, commercial, or market access teams still rely on static KOL lists or single-channel dashboards, it’s time to modernize your KEE targeting approach.
Not all influence looks the same. Some experts write guidelines, others steer trial sites, and a growing cohort shapes thinking online. Effective KEE targeting starts with segmentation that goes beyond “who is famous” to “who moves decisions and how.” Here’s a practical framework to build advanced segments from role (what the expert does), to behavior (how and where they engage), to resonance (the real-world impact of their voice).
